Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing lactococcus lactis using a murine model of Crohn's disease

Journal of Molecular Microbiology and Biotechnology

Volumn 21, Issue 3-4, 2011, Pages 138-146

  Del Carmen, Silvina ^a   De Moreno De Leblanc, Alejandra ^a   Perdigon, Gabriela ^a,b   Bastos Pereira, Vanessa ^c   Miyoshi, Anderson ^c   Azevedo, Vasco ^c   Leblanc, Jean Guy ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Genetically modified microorganisms; IL 10; Inflammatory bowel disease; Lactic acid bacteria; Lactococcus lactis; Probiotics; TNBS

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BODY WEIGHT; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOPLASM; FEMALE; FERMENTATION; INTESTINE FLUID; LACTOCOCCUS LACTIS; LIVER; MILK; MOUSE; NONHUMAN;

BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS; MURINAE; MUS;

EID: 84856500097     PISSN: 14641801     EISSN: 16602412     Source Type: Journal    
DOI: 10.1159/000333830     Document Type: Article

References (35)

1. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S: Prophylactic effect of dietary glutamine supplementation on interleukin-8 and tumour necrosis factor-σ production in trinitrobenzene sulphonic acid induced colitis. Gut 1997;41:487-493.
2. Asadullah K, Sterry W, Volk HD: Interleukin-10 therapy - review of a new approach. Pharmacol Rev 2003;55:241.
3. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L: A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-759.
4. Carroll IM, Andrus JM, Bruno-Barcena JM, Klaenhammer TR, Hassan HM, Threadgill DS: Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin-10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2007;293:G729-G738.
5. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R: Induction of intestinal inflammation in mouse by activation of proteinaseactivated receptor-2. Am J Pathol 2002;161:1903.
6. De Moreno de Le Blanc A, Chaves S, Carmuega E, Weill R, Antóine J, Perdigón G: Effect of long-term continuous consumption of fermented milk containing probiotic bacteria on mucosal immunity and the activity of peritoneal macrophages. Immunobiology 2008;213:97-108.
7. De Moreno de Le Blanc A, Chaves S, Perdigon G: Effect of yoghurt on the cytokine profile using a murine model of intestinal inflammation. Eur J Inflam 2009;7:97-109.
8. De Moreno de Le Blanc A, del Carmen S, Zurita-Turk M, Santos Rocha C, van de Guchte M, Azevedo V, Miyoshi A, Le Blanc JG: Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterology 2011;2011:1-11.
9. De Moreno de Le Blanc A, Perdigón G: Yogurt feeding inhibits promotion and progression of experimental colorectal cancer. Med Sci Monit 2004;10: BR96-BR104.
10. Del Carmen S, de Le Blanc AM, Miyoshi A, Rocha CS, Azevedo V, Le Blanc JG: Potential application of probiotics in the prevention and treatment of inflammatory bowel diseases. Ulcers 2011a; 2011:1-13.
11. Del Carmen S, de Moreno de Le Blanc A, Miyoshi A, Azevedo V, Bermúdez-Humarán LG, Langella P, Le Blanc JG: Anti-inflammatory properties of genetically modified lactic acid bacteria; in Watson RR (ed): Bioactive Foods in Chronic Disease States - Arthritis and Related Inflammatory and Autoimmune Diseases. Oxford, Elsevier, 2011b. FAO/WHO: Expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report, Cordoba, Argentina, 2001, pp 1-4.
12. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A, Pot B: Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 2007;13:236-243.
13. Han W, Mercenier A, Ait-Belgnaoui A, Pavan S, Lamine F, van S, II, Kleerebezem M, Salvador-Cartier C, Hisbergues M, Bueno L, Theodorou V, Fioramonti J: Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm Bowel Dis 2006;12:1044-1052.
14. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP: Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Eur J Pharm Biopharm 2005a; 60:349-359.
15. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP: Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multiparticulate formulation of viable, hIL-10 producing Lactococcus lactis. Eur J Pharm Biopharm 2005b; 59:9-15.
16. Kailasapathy K, Rybka S: L. Acidophilus and Bifidobacterium spp.: their therapeutic potential and survival in yogurt. Aust J Dairy Technol 1997;52:28-35.
17. Kopp-Hoolihan L: Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc 2001;101:229-241.
18. Le Blanc JG, del Carmen S, Miyoshi A, Azevedo V, Sesma F, Langella P, Bermudez-Humaran LG, Watterlot L, Perdigon G, Le Blanc AM: Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol 2011-10; 151:287-293.
19. Le Blanc JG, Garro MS, Savoy de Giori G, Font de Valdez G: A novel functional soy-based food fermented by lactic acid bacteria: effect of heat treatment. J Food Sci 2004;69:M246-M250.
20. Le Blanc JG, Van Sinderen D, Hugenholtz J, Piard JC, Sesma F, Savoy de Giori G: Risk assessment of genetically modified lactic acid bacteria using the concept of substantial equivalence. Curr Microbiol 2010:1-6. 2010;61:590-595
21. Li MC, He SH: IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004;10:620-625.
22. Marinho FAV, Pacífico LGG, Miyoshi A, Azevedo V, Le Loir Y, Guimarães VD, Langella P, Cassali GD, Fonseca CT, Oliveira SC: An intranasal administration of Lactococcus lactis strains expressing recombinant interleukin-10 modulates acute allergic airway inflammation in a murine model. Clin Exp Allergy 2010;40:1541-1551.
23. Miyoshi A, Bermúdez-Humarán LG, Azevedo MS, Langella P, Azevedo V: Lactic acid bacteria as live vectors: heterologous protein production and delivery systems; in Mozzi F, Raya RR, Vignolo GM (eds): Biotechnology of Lactic Acid Bacteria: Novel Applications. Ames, Wiley-Blackwell, 2010, pp 161-176.
24. Miyoshi A, Jamet E, Commissaire J, Renault P, Langella P, Azevedo V: A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol Lett 2004;239:205-212.
25. Moore KW, O'Garra A, Malefyt RW, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 1993;11:165-190.
26. Nouaille S, Ribeiro LA, Miyoshi A, Pontes D, Le Loir Y, Oliveira SC, Langella P, Azevedo V: Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res 2003;2:102-111.
27. Reiff C, Kelly D: Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010;300:25-33.
28. Rochat T, Bermudez-Humaran L, Gratadoux JJ, Fourage C, Hoebler C, Corthier G, Langella P: Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganesedependent catalase on DSS-induced colitis in mice. Microb Cell Fact 2007;6:1-10.
29. Sainte-Marie G: A paraffin-embedding technique for studies employing immunofluorescence. J Histochem Cytochem 1962;10:150-156.
30. Schotte L, Steidler L, Vandekerckhove J, Remaut E: Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 2000;27:761-765.
31. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
32. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin-10. Nat Biotechnol 2003;21:785-789.
33. Termont S, Vandenbroucke K, Iserentant D, Neirynck S, Steidler L, Remaut E, Rottiers P: Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance. Appl Environ Microbiol 2006;72:7694-7700.
34. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM: Interleukin-10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991;173:507-510.
35. Watterlot L, Rochat T, Sokol H, Cherbuy C, Bouloufa I, Lefèvre F, Gratadoux JJ, Honvo-Hueto E, Chilmonczyk S, Blugeon S: Intragastric administration of a superoxide dismutaseproducing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 2010;144:35-41.